Technology
Upcoming Earnings
Health

AVROBIO

$18.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.97 (5.50%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!

About

AVROBIO, Inc. Common Stock, also called AVROBIO, is a clinical stage company that engages in the development of disruptive therapies. Read More It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. The company was founded by Jeffrey Medin and Christopher Paige in 2015 and is headquartered in Cambridge, MA.

Employees
24
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
418.87M
Price-Earnings Ratio
Dividend Yield
Average Volume
171.24K
High Today
$18.69
Low Today
$17.63
Open Price
$17.71
Volume
90.12K
52 Week High
$53.70
52 Week Low
$11.85

Collections

Technology
Upcoming Earnings
Health
Biotechnology
Medical
Therapy
2018 IPO
US

News

MarketBeatMar 3

Stock Price, News, & Analysis for Avrobio

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical tria...

73

Earnings

-$2.98
-$2.15
-$1.32
-$0.49
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.57 per share
Actual
Expected Mar 21, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.